Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

In this edition of The Beat, check out how Chicago startups fared when it came to fundraising in Q2.

Biotech M&A market expected to rebound, but not IPO market Jun. 18, 2025 3:53 PM ET Bristol-Myers Squibb Company (BMY) Stock, JNJ Stock By: Jonathan Block, SA News Editor Play (3min) ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Biotechnology is certainly on the list, if not at the top, of high-growth industries in dire need of a rebound. Following enthusiasm for COVID-19 vaccines in late 2020 and part of 2021 ...

This is an amazing week to consider biotech stocks. Big news by the U.S. Food & Drug Administration (which we’ll get to momentarily) shows the benefits and outsized gains you can enjoy by ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: MoonLake ...

These Stocks Led the Market’s Big Rebound in Q2 Nvidia, Microsoft, Broadcom, and other tech names fueled the rally, while healthcare and energy stocks posted losses.

Small- and midcap biotech stocks are riskier, but have been hardest hit in the sector's decline. "Smid-cap biotech looks very cheap compared with historical levels," Yee said.